Division of Hologic Inc.
Latest From Cynosure Inc.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Despite being a slow month, megadeals abounded in February, as the medtech M&A market saw a hat-trick of billion-dollar deals. Medtech Insight recorded 12 deals for the month, on par with January's volume but down from 16 in February 2016.
Hologic is acquiring Cynosure for $1.65bn, saying medical aesthetics will complement its existing OB/GYN and women’s health businesses. It is the latest in a series of recent moves intended to accelerate Hologic’s growth.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Hologic Inc.
- Senior Management
Michael R Davin, Pres. & CEO
Stephen J Webber, EVP, CFO & Chief Accounting Officer
Douglas J Delaney, Chief Commercial Officer
- Contact Info
Phone: (978) 256-4200
5 Carlisle Rd.
Westford, MA 01886
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.